One Year Following CE MDR Clearance, Fairtility has emerged
as the AI Decision Support Platform of Choice in European Fertility
Practice
TEL
AVIV, Israel, June 7, 2023
/PRNewswire/ -- Fairtility, the transparent AI innovator powering
in vitro fertilization (IVF) for improved outcomes, announced
today its expanding geographic footprint across Europe. One
year since receiving CE MDR clearance for CHLOE EQ™, Fairtility has
established a strong presence in countries, including the
United Kingdom, Spain, Turkey, Greece, and Norway, in its mission to transform the IVF
landscape.
"Clinics across Europe have
embraced CHLOE EQ™, and they are seeing the disruptive capabilities
of the platform, both in terms of embryo selection and providing
patients the most advanced and transparent IVF experience
available," said Eran Eshed, CEO and
Co-founder of Fairtility. "These clinics are charting the path
forward as AI progresses to become part of the standard of care
across the IVF journey."
Fairtility has implemented its transparent AI tool in 10
clinics, including:
- IVF London, UK
- Harley Street Fertility Clinic, UK
- The Centre for Reproductive and Genetic Health (CRGH), UK, part
of Future Life
- MEMORIAL IVF, Turkey
- Next Fertility Murcia at Tahe Medical Center, part of Next
Clinics, Spain
- Tambre Fertility Clinic Madrid, Spain
- The Institute of Life – IASO, the leading Assisted Reproduction
(IVF) Unit, Greece
- CRA Barcelona, Spain
- Klinikk Hausken, part of Medicover, Norway
- Instituto Bernabeu, Spain
With 1 in 6 people experiencing infertility in their
reproductive years, the IVF market is growing. Fertility care
providers must expand capacity by seeking opportunities to create
workflow efficiencies both within and beyond the embryology lab.
CHLOE EQ™ represents a breakthrough in the IVF field, enabling
clinics to reduce time spent on manual embryo annotation by an
average of 33 percent per cycle. This has resulted in a 30-50
percent increase in IVF cycle capacity in clinics.
"Implementing AI technologies entering the IVF space
challenges traditional norms and drives innovation forward for
the entire industry," said Suzanne Cawood, Director of
Embryology, CRGH UK. "AI tools like CHLOE EQ™ are necessary
for improving the efficiency of IVF processes and increasing
transparency. They are also the answer to IVF professional
shortages and embryologist burnout resulting from the volume of
administration associated with a single IVF cycle. Fairtility's AI
makes IVF more efficient and accessible to the growing population
of people seeking fertility treatment."
To thrive in the digital age, clinics must embrace a fully
digital IVF journey that is streamlined and transparent for all
stakeholders. Fairtility understands this imperative and is
supporting clinics in achieving digital transformation for the IVF
journey. CHLOE EQ™ integrates with leading IVF EMR providers,
enabling data to flow freely from lab-to-fertility
specialist-to-patient, paving the path for more open communication
on treatment plans and progress.
"We selected CHLOE EQ because of its ability to provide
quantifiable biological data on embryo development, quality and
viability. This transparency and interpretability set it apart
from other AI-based decision support tools available," said
Shabana Sayed, Senior Embryologist
and IVF Lab Manager at Klinikk Hausken, part of Medicover. "Our
embryologists see this system as a companion that helps augment and
standardize decision making. It speaks to them in a language they
understand –human biology."
CHLOE EQ™ is the only commercial AI decision support
platform able to quantify biomarkers throughout embryo development,
automatically analyzing established morphological and morphokinetic
features, which are traditionally captured in a time-consuming and
subjective manner. Through translation of computational information
to biologically relevant interpretation made ready for clinical
decision making, CHLOE is the first and only transparent AI system
able to automate analysis of the full spectrum of biological events
related to embryo development.
"Together with our visionary partner clinics, we are reshaping
the fertility landscape, addressing the urgent need for improved
outcomes, and providing patients with the transparency and control
they desire," said Eshed.
About Fairtility
Fairtility is powering in vitro fertilization (IVF) through
transparent AI to improve outcomes. Equipping clinicians and their
patients with unparalleled visibility into IVF treatment, CHLOE™
(Cultivating Human Life through Optimal Embryos) is the first and
only transparent AI-based decision support tool that provides
clinicians with the biological data supporting its AI-derived
output. Beginning with CHLOE EQ™, a proprietary embryo quality
assessment platform, Fairtility is on a path to expand CHLOE™'s
application to span the full IVF journey - from infertility cause
assessment through transfer optimization. To learn more about
Fairtility™ or schedule a demo, visit our website and follow
us on Twitter, LinkedIn and Instagram.
Media Contact
Nicole Kaufman-Grubner
+1-929-588-2011
Nicole.grubner@finnpartners.com
View original
content:https://www.prnewswire.co.uk/news-releases/fairtility-expands-european-market-penetration-with-chloe-eq-as-clinics-in-five-countries-embrace-breakthrough-ai-technology-in-ivf-301845202.html